Distributes pharmaceutical and healthcare products to a retail network of more than 105,300 pharmacies and 3,600 hospitals, supported by 136 warehouses, 137 offices and 48 subsidiaries spread across 21 states and 523 districts. In FY26, the business reported revenue of Rs 6,591 crore, up 29.3% year-on-year with 31.5% like-for-like growth, while EBITDA rose 55% to Rs 266 crore at a 4.0% margin. Growth has come from a mix of like-for-like expansion and acquisitions — seven acquisitions were completed during the year, including a 51.51% stake in Anand Chemiceutics. A MedTech line has scaled to annualized revenue exceeding Rs 1,000 crore, and the company employs about 4,970 staff. Stated operating cost items are employee costs at 3.7% of revenue, other operating expenses at 2.6% and depreciation at 0.7%, with capex at 1.0% of revenue. Operating cash flow turned positive at Rs 96 crore in FY26, although Q4 FY26 absorbed Rs 114 million in one-off items including business contract closure expenses and write-offs. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceutical and healthcare product distribution, MedTech. Asset-light, low-margin pharmaceutical distribution with acquisition-led growth
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 3,922 | 5,096 | 6,591 |
| EBITDA (ex other income) | 112 | 172 | 258 |
| margin % | 2.9 | 3.4 | 3.9 |
| Owners' profit | 39 | 95 | 115 |
| EPS, as reported (₹) | 10.81 | 21.80 | 26.44 |
| ROE % · ROCE % | 2.4 · 5.8 | 6.1 · 9.7 | 8.3 · 11.6 |
| Debt / equity (x) | 0.17 | 0.17 | 0.32 |
| Cash from operations | (37) | (77) | 96 |
| Capex | (5) | (11) | (68) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,301 | 1,359 | 1,339 | 1,404 | 1,571 | 1,707 | 1,910 | 1,940 |
| Profit before tax | 35 | 39 | 37 | 36 | 45 | 40 | 58 | 67 |
| Net profit | 26 | 29 | 31 | 30 | 37 | 34 | 45 | 52 |
| EPS (₹) | 5.43 | 5.85 | 5.91 | 6.39 | 7.26 | 6.35 | 6.44 | 8.77 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| MEDPLUS HEALTH SERV LTD | 7,934 | 37.6 | 4.02 | 11.4 | 11.1 | 8.5 | — | 8.1 |
| ENTERO HEALTHCARE SOLU L ◆ | 7,864 | 62.7 | 4.49 | 29.9 | 8.3 | 8.9 | — | 5.2 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 62.7 | 20.4 | 49 of 56 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 26 Aug 2026 · Non-promoter trust sells 2.5 percent stake in Entero via block deal | ownership changes | high | — | — |
| 24 Aug 2026 · Investor meeting with Elara Capital on September 2, 2026 | board shareholder meetings | low | — | — |
| 24 Aug 2026 · Independent Director's tenure concludes at Entero Healthcare | management changes | medium | — | — |
| 19 Aug 2026 · Seven AGM resolutions approved; CEO remuneration got 93.58% support | board shareholder meetings | low | — | — |
| 19 Aug 2026 · Entero Healthcare 8th AGM concludes, all 7 resolutions passed | board shareholder meetings | medium | — | — |
| 17 Aug 2026 · Entero Healthcare Q1 FY27 earnings call: revenue up 38%, EBITDA margin hits 5% | investor communications | medium | — | — |
| 10 Aug 2026 · Earnings call recording for Q1 FY27 uploaded on company website | investor communications | low | — | — |
| 8 Aug 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| 7 Aug 2026 · Entero Q1FY27 Results: Revenue up 38%, EBITDA margin at 5% | investor communications | medium | — | — |
| 7 Aug 2026 · Q1FY27 results: Consolidated revenue up 38%, PAT up 72% | results | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 13% |
| P/B | 4.5 | 3.0 | 31 of 50 | 39% |
| ROCE | 8.9 | 5.4 | 25 of 64 | 62% |
| ROE | 8.3 | 6.6 | 25 of 51 | 52% |
| Debt / Equity | 0.3 | 0.1 | 41 of 52 | 22% |
| EBITDA margin | 5.2 | 9.4 | 36 of 50 | 29% |
| Revenue growth | 38.2 | 16.2 | 12 of 51 | 78% |
| Profit growth | 72.2 | 26.5 | 10 of 46 | 80% |
| Market cap | 7864 | 469 | 19 of 66 | 72% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
